Codiak BioSciences (CDAK)
NASDAQ:CDAK

Codiak BioSciences (CDAK) Income Statement

246 Followers

Codiak BioSciences Income Statement

Last quarter (Q3 2022), Codiak BioSciences's total revenue was $28.00K, a decrease of -97.58% from the same quarter last year. In Q3, Codiak BioSciences's net income was $-19.28M. See Codiak BioSciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 33.57M$ 22.93M$ 2.92M$ 388.00K$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 82.37M$ 92.48M$ 93.83M$ 80.54M$ 46.44M
Operating Income
$ -48.80M$ -69.55M$ -90.92M$ -80.15M$ -46.44M
Net Non Operating Interest Income Expense
$ -2.45M$ -2.67M$ -1.65M$ 1.20M$ 1.36M
Other Income Expense
$ 33.83M$ 35.07M$ 906.00K$ 992.00K$ 535.00K
Pretax Income
$ -17.42M$ -37.16M$ -91.67M$ -77.96M$ -44.54M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -17.42M$ -37.16M$ -102.50M$ -78.18M$ -58.22M
Basic EPS
$ -0.69$ -1.70$ -16.18$ -5.96$ -4.44
Diluted EPS
$ -0.69$ -1.70$ -16.18$ -5.96$ -4.44
Basic Average Shares
$ 92.47M$ 21.79M$ 6.33M$ 13.11M$ 13.11M
Diluted Average Shares
$ 92.47M$ 21.79M$ 6.33M$ 13.11M$ 13.11M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 82.37M$ 92.48M$ 93.83M$ 80.54M$ 46.44M
Net Income From Continuing And Discontinued Operation
$ -17.42M$ -37.16M$ -91.67M$ -77.96M$ -44.54M
Normalized Income
$ -15.63M$ -70.44M$ -91.67M$ -77.96M$ -44.54M
Interest Expense
$ 2.61M$ 2.70M$ 1.91M$ 300.00K$ 0.00
EBIT
$ -14.81M$ -34.46M$ -89.76M$ -77.66M$ -44.54M
EBITDA
$ -10.15M$ -28.04M$ -84.21M$ -74.89M$ -42.82M
Currency in USD

Codiak BioSciences Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis